Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, +251

The Lancet Oncology

First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine +5

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial

Timothy J. Whelan, Jim A. Julian, Tanya Berrang, +265

The Lancet

Surgical OncologyBreast OncologyRadiation TherapyMedicineExternal Beam +9

A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy

Isabel Pimentel, Ana Elisa Lohmann, Marguerite Ennis, +9

The Breast

Metastatic Breast CancerOncologyBreast OncologyMedicineMetformin Versus Placebo +7

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

Wendy A. Teft, Inna Y. Gong, B. Dingle, +10

Breast Cancer Research and Treatment

MedicineTamoxifen TherapyVitamin D StatusBreast CancerMenopause +2

Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer

Muriel Brackstone, David A. Palma, Alan B. Tuck, +9

International Journal of Radiation Oncology*Biology*Physics

Breast OncologyRadiation TherapyMedicineConcurrent Neoadjuvant ChemotherapyBreast Cancer +5

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson, Sasha Lupichuk, Kylea Potvin, +17

Breast Cancer Research and Treatment

Metastatic Breast CancerProgesterone ReceptorBreast OncologyMedicineEstrogen Receptor +6

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

Bernhard J. Eigl, Kim Chi, Dongsheng Tu, +17

Oncotarget

Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update

Scott North, Naveen S. Basappa, Joan Basiuk, +12

Canadian Urological Association Journal

Surgical OncologyCancer ManagementRenal PathologyAdvanced Kidney CancerSurgery +16

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients

Adrienne E. Borrie, Finnley A. Rose, Yun‐Hee Choi, +15

Breast Cancer Research and Treatment

Breast OncologyBreast Cancer PatientsMedicinePathologyBreast Cancer +5

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer

Adrienne E. Borrie, Rhiannon V. Rose, Yun‐Hee Choi, +17

Breast Cancer Research and Treatment

Letrozole ConcentrationBreast OncologyOncologyMedicinePathology +7